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Introduction. Alzheimer’s disease is a multifactorial disease affecting approximately twenty million 
people worldwide. Numerous variables are associated with increased risk of developing this severe 
neurological disorder. Among the risk factors, diabetes mellitus, and the ε4 isoform of the APOE gene 
have been amply demonstrated as increasing the risk of developing this disease. 
Objective. To determine if a correlation exists between APOE genotype, diabetes mellitus and 
Alzheimer’s disease.
Materials and methods. Clinical studies were carried out by surveying the clinical histories in a group 
of patients in the province of Antioquia, Colombia.  Forty-three Alzheimer’s patients were compared 
with 43 control subjects, paired by age and gender.  Commercially available methods were used to 
determine whether the patients had diabetes, and restriction enzyme-based genotyping was used to 
determine the APOE genotypes.
Results. The most common non-neurological comorbidities were: arterial hypertension, acute 
myocardial infarction, chronic obstructive pulmonary disease and hypothyroidism.  From the many 
variables investigated, two were conclusive: (1) the presence of Alzheimer’s disease was higher in 
patients with diabetes mellitus, and (2) no correlation between late-onset sporadic Alzheimer’s disease 
and APOE was found in the target population.
Conclusions.  To detect any association with the APOE genotype, a study involving much a larger 
population samples must be undertaken.
Keywords: Alzheimer’s disease, diabetes mellitus, apolipoprotein E, dementia; pulmonary disease, 
chronic obstructive.
Diabetes mellitus en pacientes con enfermedad de Alzheimer: descripción clínica y correlación 
con el genotipo APOE en una muestra de población del departamento de Antioquia, Colombia
Introducción. La enfermedad de Alzheimer es compleja y afecta, aproximadamente, a 20 millones 
de personas en todo el mundo. Muchas variables parecen aumentar el riesgo de desarrollar esta 
alteración neurológica. Entre los factores de riesgo, se ha demostrado ampliamente que la diabetes 
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mellitus y la isoforma ε4 del gen APOE tienen incidencia positiva en el desarrollo de la enfermedad. 
Se reporta un estudio en el cual se investigó la posible correlación entre APOE, diabetes mellitus y 
la enfermedad de Alzheimer, en un grupo específico de pacientes del departamento de Antioquia, 
Colombia.
Objetivo. Determinar si existe una correlación entre APOE, diabetes mellitus y la enfermedad de 
Alzheimer, en un grupo de pacientes de Antioquia, Colombia.
Materiales y métodos. Se buscaron y analizaron las historias clínicas de los pacientes con diagnóstico 
de enfermedad de Alzheimer. Se seleccionaron aquellos que cumplían los criterios de inclusión. Se 
utilizaron métodos comercialmente disponibles para confirmar la presencia de diabetes mellitus. La 
genotipificación de APOE se hizo con un método basado en la PCR y la digestión con enzimas de 
restricción, en muestras de todos los participantes en el estudio.
Resultados. En este estudio se analizan 43 casos de enfermedad de Alzheimer y 43 individuos sanos 
controles, pareados por edad y sexo. Las enfermedades concomitantes no neurológicas más comunes 
fueron: hipertensión arterial, infarto agudo del miocardio, enfermedad pulmonar obstructiva crónica e 
hipotiroidismo.
Conclusiones. De las diferentes variables investigadas, dos arrojaron resultados concluyentes: i) la 
presencia de la enfermedad de Alzheimer es más frecuente en pacientes con diabetes mellitus, y 2) no 
se encontró correlación entre la enfermedad de Alzheimer de inicio tardío esporádico y el genotipo de 
APOE.  Es importante indicar que debe llevarse a cabo un estudio con un tamaño de población mayor, 
para determinar cualquier posible correlación o inferencia con el genotipo de APOE.
Palabras clave: enfermedad de Alzheimer, diabetes mellitus, apolipoproteína E, demencia, enfermedad 
pulmonar obstructiva crónica.
Corresponding author: 
Oscar Alzate, Ph.D., 438A Taylor Hall, Mason Farm Road, 
Department of Cell and Developmental Biology, CB# 7090, 
Chapel Hill, NC 27599, USA 
Phone: (919) 962 3698; fax: (919) 966 1856
alzate@med.unc.edu
Recibido: 13/10/11; aceptado:08/03/12
(4), and neurofibrillary tangles (NFT) composed of 
aggregates of the protein tau. Other characteristics 
include synaptic dysfunction (5), decreased cerebral 
blood flow to the posterior portion of the left cingulate 
cortex (6), and cerebral endothelial dysfunction (7). 
Combinations of these and a variety of other factors 
may lead to neurodegeneration (8). Clinically, AD 
is defined by the presence of multiple cognitive 
alterations--characteristically amnesia and one 
or more of the following disturbances: aphasia, 
apraxia, agnosia, and alterations of normal executive 
functioning with progressive neurologic decline (9).
Until now, definitive diagnosis of AD has been by 
postmortem neuropathological analysis, based on 
the following observations: diffuse atrophy (mainly 
in the hippocampus, Sommer’s CA1 sector), 
decreased number of neurons in the basal nucleus 
of Meynert, hyperphosphorylated neurofibrillary 
tangles (hyperphosphorylated tau protein), senile 
plaques, granulovacuoles (tubulin) and Hirano 
bodies (actin) (10). These histopathological features 
are commonly found in the hippocampus, temporal 
cortex, and basal nucleus of Meynert (lateral 
septum). In a normally-aging brain, low levels of 
these alterations are expected, compared to the 
large amounts in an AD-affected brain (10,11).
The etiology of AD has not yet been clearly 
established (12). Both heredity and environmental 
conditions may play important roles in the onset and 
progression of AD, as suggested by the existence 
of different clinical presentations (i.e., early-onset 
Alzheimer’s disease (AD) is the most common type 
of dementia affecting memory, problem solving, 
learning, behavior and the ability to perform 
everyday activities. It is a syndrome that can be 
caused by a number of progressive disorders, 
most of which are currently the subject of intensive 
research. In the 2010 World Alzheimer Report (http://
www.alz.co.uk/research/files/WorldAlzheimer 
Report2010Executive Summary.pdf), Alzheimer’s 
Disease International estimated that approximately 
36 million people are living with dementia 
worldwide. Based on this report, nearly two-thirds 
of the affected population live in low- and middle-
income countries, where the “sharpest increases 
in affected patients are expected to occur”. People 
with AD, their families and friends are affected on 
personal, emotional, financial and social levels. 
Dementia has already affected significantly every 
health care system in the world (1,2).
AD accounts for 50-70% of dementias (3). AD 
patients are mainly characterized by a progressive 
decline in cognitive function concomitant with 
the appearance of abnormal deposits of the 
β-amyloid peptide (Aβ) called amyloid plaques 
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AD (EOAD, divided into early-onset familial or 
eFAD, and early-onset sporadic) and late-onset AD 
(LOAD, also divided into late-onset familial and late-
onset sporadic)) (12,13). Age is the most significant 
risk factor for AD (14). Autosomal dominant EOAD 
(younger than 65 years of age) has been associated 
with point mutations on the APP (amyloid precursor 
protein) or the PSN1, PSN2 (presenilin) genes. 
However, this form of the disease accounts for 
less than 5% of the total number of AD patients 
(12). The APOE gene, which codes coding for 
the apolipoprotein E (apoE), has been associated 
with increased risk of developing LOAD –the most 
common form of the disease (15).
Diabetes mellitus (DM) is characterized by chronic 
systemic hyperglycemia in which defects in 
insulin secretion, peripheral resistance to insulin 
and increased production of glucose alter the 
metabolism of carbohydrates, fats and proteins 
(16). Chronic hyperglycemia in diabetes has been 
associated with long-term damage of the eyes, 
kidneys, heart, nervous system and blood vessels 
(17,18). Four main categories of DM have been 
identified: Type 1 DM (DM1), Type 2 DM (DM2), 
other specific types and gestational diabetes (16).
Interestingly, the prevalence of DM1 and DM2 is 
increasing worldwide (19). DM increases with 
age, and, in individuals older than 60 years of 
age, the prevalence of DM has been estimated to 
be as high as 21% (20). DM prevalence is similar 
among men and women throughout most age 
ranges (10.5% and 8.8% in individuals >20 years 
of age) except for people older than sixty years 
of age, in which men present a slightly greater 
prevalence (21). More than 15 million people have 
DM in Latin America, a number that is expected to 
increase (22). The diagnosis of DM2 is usually late 
and often results from the emergence of various 
complications including retinopathy (ranging from 
16-21%), nephropathy (12-23%) and neuropathy 
(25-40%), with the result that about 30-50% of 
people suffering from DM2 are unaware of their 
condition (23).
A recent estimate suggests that diabetes is the 
fifth leading cause of death worldwide and is 
responsible for almost 3 million deaths annually 
(21). DM is included in the list of chronic non-
transmissible diseases. The magnitude of this WHO 
epidemiological category is such that it accounts for 
60% of all deaths worldwide, surpassing by a high 
margin the group of infectious diseases, including 
HIV/AIDS, TB and malaria.
DM is another risk for AD (24). The relationship 
between DM and AD has been found to be particularly 
strong in patients with the ε4 allele of APOE (APOE4) 
(25), and DM has been proposed to be associated 
with sporadic and familial LOAD (26-28).
DM2 and the APOE4 allele have been found to be 
associated with an increased amount of amyloid 
plaques in the hippocampus, increased amount of 
NFT and increased cerebral amyloid angiopathy 
(8,29,30). ApoE is a circulating lipoprotein, which, by 
binding the low density lipoprotein (LDL) receptor, 
promotes the intracellular metabolism of lipids (31-
33). This protein is vital for the normal metabolism of 
triglyceride-rich lipoproteins (32). The APOE gene 
is polymorphic, with three common alleles (ε2, ε3, 
and ε4); these are linked to different lipid metabolic 
profiles, but not showing a particular distribution in 
DM2 (34).
The APOE4 genotype increases the risk of developing 
AD (15). ApoE is important for maintenance and 
repair of neurons and apoE3 is more efficient than 
apoE4 in this regard (33). Histopathological data 
indicate that the expression of the insulin-degrading 
enzyme in the hippocampus is substantially reduced 
relative to controls, in particular in AD patients with 
the APOE4 allele (35).
The genotype displaying the highest risk for 
developing sporadic LOAD is APOE4/4 (15). 
The APOE3/4 genotype is associated with a 
medium-to-high risk for AD. APOE3/3 genotype 
has a risk factor equal to the general population. 
APOE2/3 genotype is correlated with a lower risk 
for developing AD. Those with APOE2/4, have a 
risk equivalent to APOE3/3, i.e., similar to the rest 
of the population (36). In the general population 
the frequency of the ε3 allele is 78% and of the 
ε4 allele is 13%. In patients with LOAD, the ε4 
allele frequency is 52%. In fact, homozygous 
APOE4/4 people present almost 8 times higher 
risk of developing AD compared to homozygous 
APOE3/3 people; although homozygousity for 
ε4 does not necessarily result in developing the 
disease (15,36). Among individuals from families 
with LOAD without copies of ε4, only 20% develop 
AD at around 75 years of age, compared to 90% of 
individuals with two copies of the ε4 allele (37).
In Colombia, the frequencies of the ε2, ε3, and 
ε4 alleles are similar to those reported in other 
countries. In a study conducted in 2006 in Bogotá 
involving residents between 18 and 106 years of 
age, 75% of the population were found with the 
APOE3/3 genotype, 15% were of the APOE3/4 
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genotype, 8.2% were APOE2/3, 1.4% were of the 
APOE2/4 genotype, and 0.7% of the population 
were APOE2/2 or APOE4/4 (38). Similar results 
were found by another study conducted in 2007 
involving 1,567 individuals from the Central and 
East parts of the country (39).
The glycemic dysregulation found in DM has 
been associated with brain structural damage, 
including damage in large and small vessels 
(40). Hyperglycemia can affect neural viability 
by increasing oxidative stress and formation of 
advanced glycation end-products (AGEs) (41). It 
is now considered that the AGEs play an important 
role in the pathophysiology of various neurological 
diseases via several mechanisms: (1) by modifying 
extracellular structural proteins; (2) by triggering 
intracellular processes that bind to extracellular 
receptors activating signal cascades; and (3) by 
modifying intracellular proteins.  In diabetic patients, 
the accumulation of AGEs leads to endothelial 
dysfunction among other important structural 
changes (41-43).
Hyperglycemia also has a direct effect on neural 
calcium balance in the hippocampus resulting in cell 
damage.  It may also produce hyperosmolarity and 
increase in vasopressin levels, eventually leading 
to hypothalamic neuronal degeneration (40,44). 
Altered glucose metabolism may result in decreased 
acetylcholine production, synaptic failure, and 
cholinergic neuron degeneration in the hippocampus 
(45,46). The appearance of atherosclerosis in 
cerebral arteries is also associated with DM, resulting 
in decreased cerebral blood flow and a disturbance 
in vascular reactivity causing hypoxic and ischemic 
states, which are important pathological conditions 
that can cause multiple vascular dementias (6,47,48). 
Biessels et al. (49) concluded that DM increases the 
risk of atherosclerosis and stroke, (i.e., something 
that produces a cerebral vascular disease, mediated 
by glucose toxicity and microvascular abnormalities), 
both of which lead to accelerated brain aging 
(49,50).
The accelerated formation of AGEs has been found 
to correlate with an increase in Aβ deposition, 
greater number of plaques, neurofibrillary tangles 
and elevated tau protein in the hippocampus and 
the cerebral cortex. Furthermore, accelerated AGEs 
formation is closely related to increase in oxidative 
stress (51). Insulin and glucose dysregulation can 
also alter amyloid metabolism by changing the 
insulin/insulin receptor interaction (52) and by the 
formation of AGEs (53).
DM is another risk for AD, although the molecular 
pathways connecting DM and AD are unknown (24). 
The fourth and fifth stages (known as The Honolulu 
Asia Aging Study) of the so-called “Honolulu Heart 
Program” were designed to investigate risk factors 
associated with neurodegenerative disorders and 
aging. This research program also presented 
substantial evidence that diabetes is a major 
risk factor for the development of both vascular 
dementia and AD (25). It was also found that the 
association was particularly stronger in APOE ε4 
carriers (25). Similar results were also obtained by 
the “The Cardiovascular Health Study Cognition”, a 
cohort study carried out from 1992 to 2000 (54).
Based on these previous publications in which DM2 
and the APOE genotype have been found as risk 
factors for AD, the current study was designed to 
determine if  a correlation was present among these 
variables, in a cohort of patients from the Aburrá 
Valley (province of Antioquia, Colombia), who had 
been diagnosed with AD.  Despite using a small 
population (43 cases and 43 controls), a statistically 
significant correlation was found between DM2 and 
AD. All patients and controls, selected at random 
for this study, were either APOE3/3 or APOE 2/3, 
with no ε4 alleles present. Clearly, an additional 
future study including a larger randomized sample 
is necessary before a correlation can be inferred 
between the APOE genotype and AD.
Materials and methods
The study design was a descriptive case-control 
study. The study population was composed of 
individuals residing in the towns of Medellín, 
Envigado, Itagüí, La Estrella, Bello, and 
Copacabana (Antioquia Province, Colombia). The 
population sample (n=86) was divided into two 
groups: individuals with diagnosis of AD who met 
the DSM-IVR criteria for AD diagnosis (n=43) and 
control subjects who did not meet a single DSM-
IVR criteria for AD (n=43).
AD patients were selected according to the following 
characteristics: age ≥ 65 years of age regardless 
of sex, diagnosed with sporadic LOAD by a 
neurologist, meeting the DSM-IVR clinical criteria 
for its diagnosis, and having no relatives with an 
AD diagnosis (thus selecting only for sporadic 
LOAD) or any other type of dementia. All patients 
and family members (guardian or caretaker) as 
well as the control group population participated 
voluntarily and were recruited for this study 
following the regulations of the ethics committee 
of the “Universidad Pontificia Bolivariana” and from 
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the ethics and research committee of the Instituto 
Neurológico de Colombia (INDEC).
In order to validate the diagnosis of AD, the 
following pathological conditions were ruled out: 
stroke, Parkinson’s disease, Huntington’s chorea, 
chronic subdural hematoma, normal-pressure 
hydrocephalus, cerebral neoplasm, depressive 
pseudo dementia, hypothyroidism, folic acid 
deficiency, vitamin B12 deficiency, neurosyphilis, 
HIV/AIDS, TB, Wilson’s disease, cysticercosis, 
uremic encephalopathy, hepatic encephalopathy, 
autoimmune processes, and chronic sleep apnea. 
This was done by analyzing the medical history of 
the patients (who have a long term follow-up from 
the INDEC) and retrospective corroboration with 
their families at the time of the home visit.
The control group (healthy individuals) consisted 
of persons older than 65 years of age from both 
genders, without medical history of dementia 
syndrome (9) or any other neurodegenerative 
disease. These individuals did not meet any of the 
DSM-IVR criteria for AD, had no history of stroke, 
head injury, or neurosurgery at any point in their 
lives, and had no family history of AD.
In addition, all individuals included in the study 
were evaluated for DM. INDEC patients and 
control subjects were evaluated according to their 
clinical history and by validation of the condition 
with laboratory tests using methods commercially 
available.  Individuals who were on steroids over a 
3-month period previous to this study, or who had 
any glycemic alterations resulting from steroids 
intake, were not included in this study.
Selection of individuals
The inclusion of subjects in the study was made 
on the basis of a database from the INDEC that 
included 779 medical records of patients with 
diagnosis of dementia syndrome in the Neurology 
Outpatient service, from January 2008 to July 
2009. Four hundred seventeen patients, whose 
Figure 1. Experimental design for patient selection. This flowchart explains the selection (and partial results) of medical histories 
from the database in the INDEC for the recruitment of patients.
Informed consent
Clinical evaluation
Collection of blood sample
44 families accepted
on participating
10 families: patients
were deceased
12 families:
not interested
69 families were successfully contacted
Contac the families of the 102 selected patients
Selection of patients meeting the inclusion criteria for the study:
102 patients
Selection of patients with Diagnosis of Late-onset Alzheimer s
type dementia
�
Review of medical histories with full information on the diagnosis of AD
according to the DSM-IVR criteria
Exploration of the INDEC Database for
selection of Dementia Syndrome patients
3 families: family
history of AD
HOME VISIT
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medical histories documented the clinical diagnosis 
of LOAD, were pre-selected (ICD-10 code: G30.1). 
From these, 190 were selected through meticulous 
and detailed reading of the patient’s diagnostic 
records.  Of these, 102 met the selection criteria. 
Following strict regulations of the INDEC protecting 
the privacy of the patients and their families, families 
of 69 patients were contacted, and 44 agreed to 
participate in the study–which included a home 
visit with each family. This experimental design is 
presented in figure 1.
The privacy of the participants was protected by 
dividing the research team into two groups. One 
group consisted of physicians and nurses, who 
interacted with the patients and their families, 
whereas the other team consisted of scientists 
performing molecular studies. At no point during 
this investigation did the groups exchange personal 
information. During the home visit, a physician 
from the INDEC provided a physical examination 
including a neurological exam to corroborate the 
data recorded on the medical histories (internal 
validity) and filled out a form with the patient’s clinic-
epidemiological survey. This step ascertained that 
the patient met the DSM-IVR diagnostic criteria 
for AD as already stated by the medical history. 
This meeting was followed by blood sampling (as 
described below). One patient was withdrawn from 
the group because it was confirmed that there was 
AD history in the family.
During the home visits healthy individuals were 
recruited from the community and were paired with 
AD patients according to gender and age (± 5 years). 
Control subjects met the pre-established inclusion 
and exclusion criteria and were visited by the group 
of researchers to their respective domiciles. At this 
point the clinic-epidemiological survey form was 
filled out, followed by blood sampling for laboratory 
testing.
Clinic-epidemiological survey
Since each medical history documented the 
diagnosis of AD, a complete anamnesis was 
conducted in order to confirm the information found 
in the medical history from the database. Therefore, 
each individual underwent a physical examination to 
determine the individual’s arterial pressure, weight, 
height, abdominal circumference and body mass 
index (BMI). Individuals also underwent a complete 
neurological examination, verifying the health 
status of both AD patients and control subjects and 
whether they met the DSM-IVR criteria for AD.
Blood sampling, laboratory testing and DNA 
extraction
Approximately 10 mL of peripheral blood were taken 
from each individual by venipuncture (it was made 
sure that each patient had been fasting), using 
vacuum tubes (BD Vacutainer, Becton Dickinson 
and Co., BD&C, Franklin Lakes, NJ, USA), and 
21G x 1½” needles (BD VacutainerPrecisionGlide, 
Multiple Sample Needle, BD&C). A portion of the 
blood (5mL) was collected in tubes with EDTA 
(BD Vacutainer K2 EDTA, Plus Blood Collection 
Tubes, BD&C) for extracting leukocytes which was 
the source of DNA for APOE genotyping. The rest 
of each sample (5 mL) was collected in reactant- 
and preservative-free tubes (BD Vacutainer Serum 
Blood Collection Tubes, BD&C) for blood chemistry 
analysis. Blood chemistry tests were performed at 
the clinical laboratory of the “Hospital Universitario 
Bolivariano” (University Hospital of the Universidad 
Pontificia Bolivariana). Fasting glucose levels, lipid 
profiling (total cholesterol, TC; low density lipoprotein, 
LDL; high density lipoprotein, HDL; very low density 
lipoprotein, VLDL; and atherogenic index; TC/HDL) 
were determined using standard procedures.
For DNA extraction, all chemicals were from Bio-
Rad (Hercules, California, USA) or Sigma (St. Louis, 
Missouri, USA).  Genomic DNA was extracted from 
5 mL of peripheral blood, anti-coagulated in EDTA 
following the extraction method described by Miller 
(55) with some modifications. The DNA pellet was 
allowed to dry and was resuspended in 1 mL of sterile 
type I DNAase-free H2O and stored at −20ºC until 
use. For genotyping, DNA samples were quantified 
and its quality was evaluated using Thermo Scientific 
NanoDrop 2000c by reading the absorbance of 1 µL 
of sample at 260nm. The 260/280 absorbance ratio 
was used to assess the purity of DNA. A ratio of ~1.8 
was accepted as “pure” for DNA.
Genotyping of APOE genes was carried out with PCR-
based restriction fragment length polymorphism 
(RFLP) as described by Hixson and Vernier (56) 
with some modifications. gDNA from human blood 
samples was amplified with primers (APOE-forward: 
TAAGCTTGGCACGGCTGTCCAAGGA; APOE-
reverse: ACAGAATTCGCCCCGGCCTGGTACACT 
GCC) to obtain 244bp amplicons.  Fifteen microliters 
of 2X PCR master mix (Fermentas, Glen Burnie, 
MD, USA), 300 ng of gDNA template, 1.5 µl of 10 µM 
of each primer and 2 µl of DMSO were mixed to 30 
µl reaction.  Each reaction mixture was denatured 
at 94oC for 4 min and 35 cycles of amplification 
were performed with steps of annealing at 60oC 
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Figure 2. Genotyping for APOE. Five microliters of RFLP 
products of each reaction mixture was run in 8% polyacrylamide 
gel in 1X TBE buffer for 3 hours. The polyacrylamide gels were 
stained with ethidium bromide and visualized by UV illumination. 
Lane 1: APOE4/4 homozygous, Lane 2: APOE3/3 homozygous, 
Lane 4: APOE4/3 heterozygous, Lane 3: Molecular Weight 
Standard (Bio-Rad).
for one min, extension at 72oC for two min and 
denaturation at 94oC for 30 seconds, followed 
by an extra extension step at 72oC for three min 
at the end of the cycles. Ten microliters of PCR 
product was digested in 30 µl reaction for 3 hours 
with 5 units of HhaI (New England Biolabs (NEB), 
Ipswich, MA, USA) with 20 µl of 1X buffer 4 (NEB); 
5 µl of each reaction mixture was loaded on an 8% 
polyacrylamide gel in 1X TBE buffer and run for 
3 hours under constant voltage of 10V/1cm. The 
polyacrylamide gels were stained with ethidium 
bromide and visualized by UV illumination.  As 
described by Hixson and Vernier (56), HhaI gives 
different RFLP patterns because of different 
nucleotide sequences at aminoacid numbers 112 
and 158 of ApoE2, ApoE3 and ApoE4 (figure 2).
Ethical considerations
The ethical approval for the execution of this study 
was obtained from the ethics committee of the 
“Universidad Pontificia Bolivariana” and from the 
ethics and research committee of the INDEC.
Access and extraction of data from the INDEC 
database, as well as the contact with families, was 
done with previous authorization from the Ethics 
and Research Committee of the INDEC. Information 
about the study, including its objectives and 
methods, was provided by telephone to the families 
or caretakers of the patients. The home visit was 
agreed to by the families, or directly with the control 
subjects. On each visit, a written informed consent 
was obtained from families or caretakers who 
signed it voluntarily, and all questions concerning 
the study were adequately addressed. Protecting 
the principles of autonomy, respect for the dignity 
of individuals and beneficence were always a top 
priority. All the information obtained during the 
study was confidential.  Individuals were assigned 
with a code in order to protect their identities.
Statistical analysis
The information was obtained and recorded on the 
clinic-epidemiological survey form, then transferred 
into a database created with Microsoft Excel®. 
Central tendency and non-parametric measures 
were calculated (χ2, confidence intervals (CI), 
relative risk (RR)). Statistically significant data 
were interpreted with a p-value < 0.05 and their 
respective confidence intervals.
Results
Forty-three AD cases and 43 control subjects were 
paired according to their age and gender.  The 
percentage of females in both groups was 53.5%, 
with an average age for AD cases of 80.9 years 
(SD=6.7) and the average age for controls 81.7 
years (SD=7.5).
The most common non-neurological comorbidities 
were as follows: arterial hypertension (53.5% for 
AD cases and 65.1% for control subjects), acute 
myocardial infarction (11.6% for AD cases and 4.7% 
for control subjects), chronic obstructive pulmonary 
disease (18.6% and 4.0%), hypothyroidism 
(18.6% and 11.6%), smoking (65.1% and 27.9%), 
alcohol consumption (39.5% and 16.3%), any 
form of cancer (16.3% and 7.0%), heart failure 
(11.6% and 7.0%) and dyslipidemia (9.3% and 
16.2%).  Comorbidities were determined from the 
medical histories of the population under study 
and subsequently confirmed with the families of 
the AD patient and by direct interview with the 
control subjects. The rest of the clinical diagnosis 
and history is presented in table 1.
When the  non-neurological comorbidities in both 
groups were compared, significant statistical 
differences were present for renal failure and 
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smoking (this was the subject status only at the 
time of analysis; since no long term follow-up 
was conduted, no conclusions were possible as 
to whether or not these comorbidities are directly 
associated with AD or if they represent a causal 
relationship to AD). The most common neurological 
comorbidities were head trauma (11.6% and 7.0%) 
and epilepsy (9.3% and 2.3%), without statistically 
significant differences. The clinical pathology findings 
for neuropsychological and neurological evaluation 
showed statistically significant differences as shown 
in table 2.
All patients met the DSM-IVR criteria for the diagnosis 
of AD, displaying in each of them statistically significant 
differences compared to the control subjects, as 
shown in table 3. Most individuals in both groups 
presented normal body mass index (BMI) (62.5% for 
AD patients and 68.8% for control subjects).  Only a 
quarter of the population was found to have a BMI 
above normal, 22% in the case group and 28.1% 
for the control group, as outlined in table 4.
At the time of the home visit, all participants 
underwent a clinical assessment and blood 
samples were taken for blood chemistry testing. 
The values determined for the variables measured 
are presented in table 5. No significant differences 
were found in either group. Regarding the presence 
of alterations in blood glucose levels, eleven of the 
AD patients (25.6%) and one of the control subjects 
were diagnosed with DM2 (statistical significance, 
χ2 with Yates’ correction = 9.68, p = 0.002). Diabetic 
nephropathy, two diabetic retinopathies, and one 
diabetic foot were diabetic complications found in 
the AD population. Diabetes was found 14 times 
more in AD patients than in control subjects (Odds 
Ratio 14.4, 95% CI 1.7-117.7).
Genotyping studies for APOE indicated that 89% of 
the population was of the APOE3/3 genotype, while 
the remaining 11% was of the APOE2/3 genotype. 
No ε4 allele was found. When evaluating the 
frequencies of the APOE genotypes in the group 
of patients and in the group of control subjects, the 
Table 1. Description of non-neurologic and neurological comorbidities in the AD and control groups
Non-neurological and % %
neurological comorbidities  AD Cases Controls OR (CI95% OR) X2 p-value
 (n=43) (n=43) 
 
Arterial hypertension 53.5 65.1 0.61 (0.25-1.46) 1.20 0.272 
Acute myocardial infarction 11.6 4.7 2.67  (0.49-14.73) 1.40 0.237
Angina pectoris 2.3 9.3 0.23  (0.02-2.16) 1.91 0.167
Heart failure 11.6 7.0 1.75  (0.39-7.85) 0.55 0.458
COPD 18.6 4.0 3.04  (0.75-12.39) 2.61 0.106
Arthritis 4.7 2.3 2.04  (0.17-23.47) 0.43 0.557
SLE 0.0 0.0  - - -
Hypothyroidism 18.6 11.6 1.73  (0.51-5.81) 0.81 0.366
Hyperthyroidism 0.0 0.0  - - -
Hepatitis B or C 0.0 0.0  - - -
Malnutrition 2.3 0.0  - 1.01 0.314
Renal failure 0.0 9.3 2.02  (1.63-2.51) 4.19* 0.041
Liver failure 0.0 0.0 - - -
Cancer 16.3 7.0 2.59  (0.62-10.78) 1.81* 0.178
Malaria 0.0 0.0 - - -
TB 0.0 0.0 - - -
HIV/AIDS 0.0 0.0 - - -
Cigarette smoking 65.1 27.9 4.82  (1.93-12.04) 11.95 0.001*
Alcohol consumption 39.5 16.3 3.36  (1.21-9.27) 5.78* 0.061
Stroke 4.7 7.0 0.65  (0.10-4.11) 0.21* 0.615
Head trauma 11.6 7.0 1.75  (0.39-7.85) 0.55* 0.458
Primary neoplasm of CNS 0.0 0.0 - - -
Metastasis to CNS 0.0 0.0 - - -
Migraine 2.3 0.0 - 1.01* 0.314
Multiple sclerosis  0.0 0.0 - - -
Epilepsy 9.3 2.3 4.30  (0.46-40.23) 1.91* 0.167
Parkinson’s disease 4.7 2.3 2.09  (0.18-23.47) 0.34* 0.557
χ2 with Yates’ correction; COPD: Chronic obstructive pulmonary disease; SLE: Systemic lupus erythematosus; TB: tuberculosis; 
HIV: Human immunodeficiency virus; AIDS: Acquired immunodeficiency syndrome; CNS: Central nervous system. 
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distribution was comparable to that found in the 
analysis of the total population (38,39).
Discussion
Many studies have been undertaken to identify 
potential risk factors for AD. Vascular factors 
such as arterial hypertension, dyslipidemia, 
Table 2. Description of neuropsychological and neurological evaluation
 %  %  
 AD Cases Controls OR  χ2 p-value
 (n=43) (n=43) (CI95% OR)
Neuropsychological evaluation  55.5 4.7 23.57  (5.05-110.03) 24.87* <0.001
Neurological evaluation  46.5 4.7 17.82  (3.82-83.20) 19.79* <0.001
Physical examination signs
Palmar grasp reflex 60.5 2.41 62.71  (7.89-499.83) 33.07* <0.001
Sucking reflex 55.8 0.0 -  33.05* <0.001
Glabellar reflex 44.2 14.3 4.75  (1.66-13.62) 9.8*  0.007
Palmomental reflex 41.9 0.0 -  22.87* <0.001
Gait abnormality 53.5 21.4 4.22  (1.63-10.90) 9.88*  0.007
Posture abnormality 51.2 19.0 4.45  (1.68-11.80) 10.19  0.006
Balance abnormality 42.2 14.3 4.75  (1.66-13.62) 9.80  0.07
Motor impersistence 41.9 0.0 -  22.87* <0.001
Motor Perseverance 18.0 0.0 -  9.46*  0.009
Verbal Perseverance 27.9 2.4 15.87  (1.96-128.66) 11.34  0.003
Lower-limbs hypertonicity 20.0 0.0 -  26.05* <0.001
Table 3. DSM-IVR Diagnostic Criteria for Alzheimer’s disease
Diagnostic criteria % Cases % Controls OR χ2 p-value
 (n=43) (n=43) (CI95% OR) 
1.1 Memory Impairment  100.0 4.7 - 78.35* <0.001
1.2 One or more of the following cognitive  100.0 2.3 - 82.09* <0.001
disturbances: aphasia, apraxia, agnosia, 
disturbance in executive functioning.  
2. The cognitive deficits in criteria   100.0 0.0 - 86.0 <0.001
1.1 and 1.2 each cause significant
 impairment in social or occupational 
functioning and represent a significant 
decline from a previous level of social functioning. 
3. The course is characterized by gradual onset  100.0 2.3 - 82.09 <0.001
and continuing cognitive decline.  
4. The cognitive deficits in criteria 1.1 and 1.2  are 100.0 0.0 - 86.0 <0.001
not due to any nervous, systemic or substance-
induced conditions. 
5. The deficits do not occur exclusively during the  100.0 0.0 - 86.0 <0.001
course of a delirium.  
Table 4. Body mass index in both groups
Category % Cases % Controls OR (IC95% OR) χ2 p-value
 (n=43) (n=43)  
Underweight 15.6 3.1 0.18  (0.01-1.88) 3.01* 0.389
Normal 62.5 68.8  1.00
Overweight 9.5 12.5 1.21  (0.19-7.989)
Obesity 12.5 15.6 1.14  (0.22-6.02)
hyperinsulinemia and DM2, obesity, subclinical 
atherosclerosis and arrhythmias have been 
associated with high risks of cognitive impairment 
and dementia (52). Studies in Latin America have 
also shown that metabolic syndrome doubles the 
risk of cognitive impairment (57). Kalaria (58) has 
indicated that the gradual adoption of westernized 
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lifestyle involving excessive caloric intake, 
unhealthy diet, and decreased physical activity, 
favors the appearance of conditions such as AD. 
In the Honolulu-Asia Aging study (25), a significant 
association was found between diabetes, alone or 
combined with the APOE ε4, with an increase in 
the incidence of dementia and neuropathological 
outcomes in a cohort of 2,574 Americans of 
Japanese origin. This study associated diabetes 
with total dementia (RR 1.5, 95% CI 1.0-2.2) 
and with AD (RR 1.8, CI 1.1-2.9).  Another study 
(59,60) found an RR of 1.3 (95% CI 0.9-2.1) for 
AD. Despite the large differences in the sizes of 
the sample populations, similarities occur between 
these reports and the current findings (the strength 
of a positive association between DM and AD) in 
which paired analysis found statistically significant 
correlation between AD and DM (χ2 McNemar: 
8.18, p= 0.004, with a minimum of 95% CI and OR 
of 1.90), suggesting that even at a small scale there 
is a significant correlation. In the most recently 
published study (24), Ohara et al. showed that 
subjects with diabetes display a higher incidence 
of all-cause dementia, AD, and vascular dementia 
than control subjects with normal glucose tolerance 
(all-cause dementia: adjusted hazard ratio [HR] = 
1.74, 95% CI 1.19-2.53, p=0.004; AD [HR] = 2.05, 
95% CI 1.18-3.57, p=0.001).
In the current study, the most common non-
neurological comorbidities were as follows:  arterial 
hypertension (53.5% for AD patients and 65.1% 
for control subjects), acute myocardial infarction 
(11.6% for AD cases and 4.7% for control subjects), 
chronic obstructive pulmonary disease (18.6% 
and 4.0%), hypothyroidism (18.6% and 11.6%), 
smoking (65.1% and 27.9%), alcohol consumption 
(39.5% and 16.3%), cancer (16.3% and 7.0%), 
heart failure (11.6% and 7.0%) and dyslipidemia 
(9.3% and 16.2%).
Type 1 and type 2 DM have been associated with 
a progressive decline in cognitive functioning, 
mainly in elderly patients (49,50,61). Toxic effects 
of high glucose levels are mediated through an 
enhanced flux of glucose through the polyol and 
hexosamine pathways, disturbances of intracellular 
second messenger pathways, an imbalance in the 
generation and scavenging of reactive oxygen 
species, and by advanced glycation of important 
functional and structural proteins (49). In addition, 
DM2 is a risk factor for atherosclerosis of the carotid 
and intracranial arteries, thus increasing the risk of 
stroke, cognitive decline, and dementia (62,63). In 
the current study, eleven AD cases (25.6%) and 
one control subject (2.3%) were given a diagnosis 
of diabetes--all DM2, representing a statistically-
significant difference (p=0.002). However, these 
results do not imply any causal relationship. The 
observations are a “one-time-point” observation, 
and not a follow-up study, and therefore, one 
cannot conclude from these data that DM leads to 
an increase in the risk of developing AD.  However, 
this conclusion was reached by Ohara et al. (24) in 
a 15-year follow-up study.
In the current study sample, smoking with an OR 
of 4.82 (95% CI 1.93-12.04) suggested it as a risk 
factor for AD. In general, the literature is inconsistent 
on this subject.  For instance, several studies (64-
66) have reported evidence linking smoking more 
Table 5. Description of variables measured quantitatively in both groups
Variables Average Average t-test p-value
 (SD) (SD)
 Cases Controls
 (n=43) (n=43) 
Systolic Arterial Pressure (mm Hg) 129.9  (16.1) 128.5  (16.3) 0.08 0.771
Diastolic Arterial Pressure (mm Hg) 70.9  (11.0) 75.3  (10.1) 0.37 0.541
BMI 23.8  (7.0) 24.7  (4.2) -068 0.493
Abdominal circumference (cm) 91.7  (12.2) 92.8  (12.3) 0.08 0.769
Glycemia (mg/dL) 90.8  (31.0) 80.7  (12.5) 3.31 0.072
Total cholesterol (TC) (mg/dL) 201.0  (36.9) 212.7  (37.5) 0.00 0.998
Triglycerides (TG) (mg/dL) 155.0  (64.5) 154.8  (67.7) 1.04 0.310
HDL (mg/dL) 47.3  (12.2) 57.1  (12.3) 0.07 0.931
LDL (mg/dL) 121.9  (31.1) 124.5  (35.4) 1.04 0.309
VLDL (mg/dL) 31.0  (12.9) 30.9  (13.4) 0.99 0.322
TC/HDL 4.3  (1.0) 3.9  (1.2) 1.35 0.248
mm Hg: millimeters of mercury; BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; VLDL: very 
low-density lipoprotein; TC/HDL: total cholesterol/high-density lipoprotein ratio. 
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as a protective factor than as a risk factor for AD. 
The meta-analysis of 19 prospective studies by 
Anstey, et al. (67), a total of 27,374 participants 
evaluated for dementia, reported a relative risk of 
1.79 (95% CI 1.43-2.23) for AD among smokers and 
nonsmokers (67). A number of studies reflect the 
lack of association between these factors (68,69). 
Given the increasing prevalence of dementia and 
the high burden of comorbidity, morbidity, and 
disability, an urgent need is developing to clearly 
identify whether smoking is a modifiable risk factor 
for AD.
Among the most prevalent chronic diseases is 
chronic obstructive pulmonary disease (COPD). 
In the current study, COPD was found in 18.6% of 
patients with AD compared with 7% in the control 
patients.  However, the number of patients was not 
sufficient for concluding an association with COPD. 
Regarding the presence of cancer, no correlation 
appears between the presence of cancer and AD 
(16.3% vs. 7.0% control patients).  These data are 
similar to those in other studies, e.g.,12.15% for AD 
patients versus 10.11% for control subjects (70).
Finally, the present study is to be considered a 
preliminary work in which a correlation between 
APOE genotype, DM, and AD was sought in a 
specific population. Studies are planned to extend 
these comparisons to a larger and more diverse 
population in future.
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